[Skip to Navigation]
Access to paid content on this site is currently suspended due to excessive activity being detected from your IP address Please contact the publisher to request reinstatement.
October 2004

Efficacy and Safety of 5% Imiquimod Cream in Treating Patients With Multiple Superficial Basal Cell Carcinomas

Arch Dermatol. 2004;140(10):1284-1285. doi:10.1001/archderm.140.10.1284-b

There has been increasing interest in the use of 5% imiquimod cream in the treatment of patients with superficial basal cell carcinomas (sBCCs). To date, the reports of its efficacy apply to single tumors in individuals.1-3 However, in clinical practice it is common for patients to have more than 1 sBCC when they present for treatment.4 The aim of this study was to assess the safety and efficacy of 2 dosing regimens of 5% imiquimod cream for the treatment of patients with multiple sBCCs.